The project, which started in the spring of 2018, was completed with a total cost of about HUF 7 billion and received a grant of more than HUF 1 billion based on Individual Government Decision (EKD/TECH-2018/5).

As part of the investment package, Egis has completed its oncology product development and manufacturing infrastructure. In the newly established finished product manufacturing plant - used for products that require special manufacturing conditions - the company has installed equipment that enables state-of-the-art technological innovations.

"With our new investment, all steps of the development and manufacturing of oncology products can be implemented at Egis. Thus, we can contribute to the treatment of oncology patients with up-to-date generic products that are, regarding all processes, fully controlled and reliable, domestically developed and manufactured " - said Dr. István Hodász, CEO of Egis Pharmaceuticals PLC.

As another element of the investment package that was now inaugurated, Egis set up a new packaging plant as well. The company’s Körmend site performs more than half of the company's packaging tasks, the old packaging plant has been operating at full capacity, and there was no possibility of expanding it.  The new packaging plant, located on the property purchased at the beginning of 2018 and adjacent to the production site, can be further expanded in the future, and will be able to meet the growing market demands with flexibility.

The facility complies with both international quality assurance requirements (GMP) and standards for the validation of computerized systems and electronic data processing, while being suitable for the temporary storage of finished products and for product serialization that supplements manufacturing processes and certifies authenticity.